The Short Answer: Disclosure Matters More Than a Washout Date
If you have cosmetic Botox booked or recently done and an operation under general anesthesia or deep sedation coming up, search results offer every possible answer. In a long-running RealSelf question thread about Botox around a general anesthetic, physicians answering between 2011 and 2015 wrote that toxin is safe “at any time,” and several said they had injected patients while under general anesthesia for other procedures; another answer in the same thread recommended waiting three weeks before or after surgery. A Sarasota Surgical Arts blog post on breast augmentation says many surgeons recommend one to two weeks so injection side effects resolve. A New Jersey plastic surgeon’s blog advises roughly three to four months, but only when the treated muscle sits inside the surgical field. A video featured on the American Society of Plastic Surgeons’ botulinum toxin page, titled “Planning Plastic Surgery Around Botox and Fillers,” notes that before a bigger procedure “you may be asked to have time go by.”
These answers are less contradictory than they look, because they respond to different questions. None of them is a tested safety threshold. The FDA prescribing information for BOTOX Cosmetic, revised in October 2024, does not set a Botox-free interval before anesthesia, and we found no clinical trial that compared surgical or anesthetic outcomes by time since a cosmetic injection. What the label does contain is narrower and more useful: cautions about specific drug classes used around surgery, a boxed warning about distant spread of toxin effect, and a Medication Guide that asks patients to say whether they “have plans to have surgery.”
So the decision in front of you is mainly a disclosure decision. Two sets of clinicians each hold half of the picture: your injector, and your surgeon and anesthesia team. The sections below explain what each quoted wait is actually for, what the label and the case literature say, and exactly what to tell each side. They do not give you a safe interval to calculate yourself. That call belongs to the clinicians who know the operation, the anesthetic and the drugs planned.
| Advice you may see | Where it appears | What it is meant to handle | What it does not settle |
|---|---|---|---|
| “Safe at any time”; toxin given under general anesthesia | Several physician answers in a RealSelf Q&A thread (2011–2015) | Reflects those physicians’ experience that they know of no problems between toxin and general anesthesia | Does not engage the label’s interaction cautions or the facial twitch-monitoring problem; opinion, not tested evidence |
| “A week or so” to one to two weeks before surgery | Sarasota Surgical Arts blog on Botox before breast augmentation | Lets injection-site bruising or swelling settle before the operation; pairs the wait with telling the surgeon about recent injections | The toxin effect is still active: the label describes onset in one to two days and about three to four months of effect for frown lines |
| Three weeks before or after surgery | One answer in the same RealSelf thread | Offered as a general recommendation | No reason or evidence is given for the number |
| About three to four months when the treated muscle is in the operative field | Better Plastic Surgery blog (plastic surgery practice, 2026) | Lets the muscle return to baseline before the face is measured and marked, for example before a lip lift | Framed by that surgeon as an accuracy issue, not a safety one; does not automatically apply to surgery elsewhere on the body |
Notice what the table leaves out: none of these waits claims to flush the toxin out of your body, and none was derived from outcome data. As the next section shows, the labeled effect does not live in your bloodstream. It lives at the treated nerve endings, for months, which is why the useful question is “who needs to know?” rather than “how long until it is gone?”
What the FDA Label Actually Says About Anesthesia-Adjacent Drugs
The current BOTOX Cosmetic prescribing information opens its drug-interaction section with an important qualifier: “No formal drug interaction studies have been conducted.” Every caution below is therefore precautionary pharmacology, not a measured rate of harm at cosmetic doses. Within that limit, the language is specific:
Section 7.1, aminoglycosides and other agents interfering with neuromuscular transmission: co-administration “with aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.”
Section 7.4, muscle relaxants: “Excessive weakness may also be exaggerated by administration of a muscle relaxant before or after administration of BOTOX Cosmetic.” The therapeutic BOTOX prescribing information carries the same sentence for BOTOX.
Highlights: patients receiving the toxin together with aminoglycosides, curare-like agents or muscle relaxants “should be observed closely because the effect of BOTOX Cosmetic may be potentiated.”
Section 7.3, other botulinum toxin products: the effect of giving different botulinum toxin products at the same time or within several months of each other is unknown.
A note on jargon. In anesthesia, “curare-like” refers to the non-depolarizing neuromuscular blocking drugs, the paralytic medicines used to relax muscles for a breathing tube and for many operations. Atracurium and cisatracurium, which appear in the studies discussed below, belong to that group. Aminoglycosides are one specific class of antibiotics. The label names classes; it does not say that every surgical antibiotic or anesthetic interacts with Botox. Whether any drug planned for your operation falls into those classes, and what to do about it, is a decision for the surgical and anesthesia team, not something to negotiate from a label excerpt.
Why those classes? According to the label’s mechanism section, the toxin binds to motor nerve endings and blocks release of acetylcholine, the chemical signal that tells a muscle to contract, by cleaving a nerve-ending protein called SNAP-25. Paralytic drugs used in anesthesia act on the muscle side of the same junction. In a rat study published in Anesthesia & Analgesia, investigators concluded that a single toxin injection decreases “the margin of safety” of nerve-to-muscle transmission through effects on both sides of that junction. That is the plausible reason a label would ask clinicians to watch for an added effect, even though no one has measured its size at cosmetic doses.
What the Medication Guide asks you to disclose
The FDA-approved Medication Guide inside the same labeling turns these cautions into patient instructions. Before treatment, it asks you to tell your doctor if you “have plans to have surgery,” have “had surgery on your face,” have a disease that affects your muscles and nerves, or have swallowing or breathing problems. Among medicines, it singles out whether you “have recently received an antibiotic by injection,” “take muscle relaxants,” take anti-platelet or anticoagulant medicines, or have received any other botulinum toxin product in the last four months. It also says: “Do not start any new medicines until you have told your doctor that you have received BOTOX or BOTOX Cosmetic in the past.”
Read together, those lines are the label-level basis for the two-way disclosure this article recommends. Your injector needs to know your surgical plan. And anyone starting new drugs around your operation, which in practice includes the anesthesia team, needs to know your toxin history. This article quotes the BOTOX labeling; Dysport, Xeomin, Jeuveau, Daxxify and other products have their own labels, so the team should check the one for the product you actually received.
Why “washout” is the wrong mental model
The label says the toxin produces chemical denervation of the injected muscles one to two days after injection, increasing in intensity during the first week, and that the duration of effect for glabellar (frown) lines is approximately three to four months. Its pharmacokinetics section adds that, with currently available technology, the toxin cannot be detected in peripheral blood after intramuscular injection at the recommended doses. The effect sits at the treated nerve endings rather than circulating, so “waiting for it to leave your system” misdescribes what is happening.
The practical consequence is easy to miss. Someone treated eight to ten weeks before surgery may still have an active effect in those muscles, even if they have stopped thinking of it as a current treatment. That is exactly why the date and areas belong on the pre-operative record, the same way a recent prescription would.
How Cosmetic Botox Can Mislead an Anesthesia Twitch Monitor
During many general anesthetics, the team uses a peripheral nerve stimulator to judge how deeply a paralytic drug is working. In a “train-of-four” test, four small electrical pulses are delivered to a nerve and the clinician counts the resulting muscle twitches: fewer twitches suggest deeper blockade, and zero of four suggests very deep blockade. The site matters. Stimulating the facial nerve relies on muscles around the eye and brow, the same region many people treat cosmetically. A muscle already weakened by toxin can stay still regardless of how much paralytic drug is actually reaching the rest of the body.
The best-documented example is a 2019 case report in Eplasty by Le and colleagues. A 61-year-old woman was in a cardiothoracic intensive care unit after mitral valve replacement and atrial septal defect repair. Her course was complicated by cardiogenic shock and acute respiratory distress syndrome, and she received a continuous infusion of the paralytic drug cisatracurium as part of lung-protective ventilation. For several days, facial-nerve testing showed 0 of 4 twitches, which was documented as complete paralysis. When the team noticed she was out of sync with the ventilator, they moved the stimulator to the ulnar nerve at the wrist and saw twitches, evidence of inadequate paralysis. Cisatracurium was then titrated until adequate blockade was reached.
The likely explanation surfaced afterward. Her health care agent disclosed a number of previously undisclosed cosmetic procedures, and the authors presumed that an unreported Botox injection had interfered with facial-nerve testing. They could not confirm it with the patient. Her condition continued to deteriorate, her family chose to withdraw care, and she died several days later; the report does not attribute her death to the toxin. This was not a routine elective operation, and it is one case. What it documents is a measurement problem: cosmetic history was missing from the record, and a monitor reading was trusted until other clinical signs contradicted it.
It is not an isolated observation. The Eplasty authors cite case reports dating back to 2006, by Ward and Harrop-Griffiths (2006), Kuczkowski (2007), Dunne and colleagues (2012) and Cross (2016), that describe incomplete paralysis despite 0 of 4 facial-nerve twitches in patients treated with Botox. The Frick rat study separately cites a 2006 Anesthesiology report in which a twitch pad on the forehead of a patient who had toxin in the muscle around the eye misled the anesthesiologist’s assessment of blockade in the abdomen.
The direction of the error matters. A toxin-treated facial muscle makes the patient look more paralyzed than the rest of the body is. If drug dosing is titrated to that reading, blockade elsewhere can be lighter than intended, which the Eplasty authors describe as “suboptimal neuromuscular blockade when titrated to facial nerve stimulation testing.” Their recommendations follow from that:
Monitor neuromuscular function at the ulnar nerve “whenever possible.”
Avoid overreliance on a single parameter, such as the train-of-four reading, when other clinical signs disagree.
Screen all patients before surgery for prior Botox use, “regardless of age or youthful appearance.”
Have plastic surgeons teach patients to disclose all cosmetic procedures to future doctors, “no matter how minor they may view it.”
What the rat study adds, and what it cannot tell you
Frick and colleagues (Anesthesia & Analgesia, 2012) injected 2.5 Units of botulinum toxin into one hind-limb muscle of rats and compared them with saline-injected controls. Sixteen days later, the toxin-injected muscle needed far less of the paralytic drug atracurium for the same effect: the dose that halved twitch strength (the ED50) was 0.23 mg/kg versus 0.72 mg/kg in controls, about one-third. The ED50 was also lower on the opposite, uninjected leg, and muscle wasting extended to neighboring muscles, which the authors read as effects at a distance from the injection site.
The authors drew two monitoring conclusions. A twitch pad over a toxin-injected area “may provide incorrect information regarding the rest of the body,” and, because of the distant effects, monitoring “even at other sites” may not accurately reflect paralysis elsewhere. They also wrote that increased sensitivity to non-depolarizing blockers “has to be anticipated.”
The limits are just as important. These were rats, a limb muscle, one dose that is not equivalent to adult facial cosmetic dosing, and a time point that may not match any patient’s surgery date. The study shows a plausible mechanism; it does not give a human risk, and it does not give a safe interval. Its practical takeaway matches the case reports: the anesthesia team can only account for the toxin if they know where and when it was injected.
Why Surgeons Still Ask for a Gap: Bruising and Measurement
If the anesthesia concerns mostly come down to disclosure, why do surgeons still ask for time between an injection and an operation? The practice sources point to two concrete reasons, and neither of them is “clearing the toxin.”
Injection-site bruising and swelling
The Sarasota Surgical Arts post on Botox before breast augmentation says injections can cause minor bruising or swelling that usually subsides within a few days, and that many surgeons recommend waiting one to two weeks between Botox and surgery so side effects have fully resolved. The same page tells patients that, because they will be under anesthesia, they should let the surgeon know about any recent cosmetic injections. That is one practice’s scheduling convention, not a tested threshold, but its logic is easy to follow: nobody wants a fresh, unexplained bruise or a swollen injection site on the day of surgery.
Bleeding risk adds a medication layer. The Medication Guide asks patients to tell the injector about bleeding problems and about anti-platelet or anticoagulant medicines. If your surgeon has changed your blood-thinner instructions around the operation, tell your injector rather than adjusting anything yourself; our guide to blood thinners and supplements before injectables covers that side of the question in more detail.
Measuring a temporarily altered face
For facial surgery, the bigger reason is accuracy. In a practice blog post, Morristown, New Jersey plastic surgeon Farhad Rafizadeh describes surgical planning as a series of measurements taken at rest and in animation: where the brow sits, how much upper-eyelid skin is truly redundant, how long the philtrum is, and how much tooth shows with the lips relaxed. He notes that a neuromodulator changes several of those values for three to four months and then gives them back. His stated rule is that if the treated muscle sits inside the surgical field, it should recover before the face is measured and marked; if it does not, such as frown-line Botox before a lip lift, there is usually nothing to wait for.
A lip flip before a lip lift is his clearest example, because the toxin temporarily changes the exact lip position the operation is designed to correct. The same reasoning applies to procedures in which a surgeon judges brow and lid position, such as eyelid surgery. If you are unsure whether your treated areas overlap the operation, that is a question for the surgeon at consultation, ideally before you book the next injection.
The same blog states there is “no established interaction” between cosmetic-dose toxin and modern anesthetic agents at facial-aesthetic doses, and treats telling the anesthesiologist as routine. That is one surgeon’s position. It fits the label’s lack of definitive serious distant-spread reports at cosmetic doses, but it does not engage the label’s interaction cautions or the monitoring case reports above, which is why this article treats disclosure as necessary rather than as a formality.
What the facelift complication study does and does not show
The study often cited for “injectables do not make surgery riskier” is a retrospective chart review by Salsberg and Motakis in Dermatologic Surgery (2026; published online December 2025). Across 15 months of deep-plane facelifts, 57% of patients had prior injectables. Complications occurred in 16% of those patients versus 8% of patients with no prior injectables, a difference that was not statistically significant (p = .188).
Two limits matter for a Botox reader. First, the prior injectables recorded in the abstract were fillers (hyaluronic acid, calcium hydroxylapatite and poly-L-lactic acid); botulinum toxin is not listed among them. Second, a small single-practice series in which the complication rate doubled but missed statistical significance cannot prove equivalence. It is reasonable evidence that prior filler did not clearly raise facelift complications in that practice. It says nothing about toxin and anesthesia. For the filler side of surgical planning, see our article on whether filler affects a future facelift.
What to Tell Your Injector—and What to Tell the Surgical Team
The Eplasty authors open their report with the core problem: cosmetic Botox has become so common that many patients “do not always consider it to be a past surgical procedure,” so it goes missing from the medical record. You can close that gap yourself. Do not wait to be asked about cosmetic treatments; volunteer them, in both directions.
| Tell | What to share | Why it matters |
|---|---|---|
| Your injector | Surgery date, the type and site of the operation, and whether general anesthesia or sedation is planned | The Medication Guide asks whether you have plans for surgery or have had facial surgery; the injector can avoid muscles in the surgical field and avoid fresh bruising close to the date |
| Your injector | Recent or planned injected antibiotics, muscle relaxants, and any blood-thinner changes your surgeon has made | These are the drug classes the label and Medication Guide single out; the injector can postpone, adjust, and document the conversation |
| Your injector | Any nerve-muscle disease, swallowing or breathing problem, and any other toxin product received in the last four months | Label sections 5.6, 5.7 and 7.3 flag these as reasons for caution or as combinations with unknown effects |
| Surgical and anesthesia team | Exact product name, such as BOTOX Cosmetic, Dysport, Xeomin, Jeuveau or Daxxify | The label states Units cannot be compared or converted between products, so “20 units” means little without the product name |
| Surgical and anesthesia team | Areas treated: forehead, frown lines, crow’s feet, lips, jaw or neck | Helps the anesthesia team choose a twitch-monitoring site away from treated muscles, and helps the surgeon judge whether the operative field is affected |
| Surgical and anesthesia team | Approximate total units and the date of the most recent session | Places you on the labeled timeline (onset in one to two days, building through the first week, about three to four months for frown lines) and separates cosmetic from therapeutic dosing |
| Surgical and anesthesia team | Any new weakness, drooping eyelids, double vision, voice change, or trouble swallowing or breathing since the injection | These are boxed-warning symptoms; they warrant prompt medical care in their own right and must be known before airway management |
flowchart TD
P["You: toxin treatment and a planned operation"] --> I["Tell your injector"]
P --> S["Tell your surgeon and anesthesia team"]
I --> I1["Surgery date, site and anesthesia type"]
I --> I2["Injected antibiotics, muscle relaxants, blood-thinner changes"]
I --> I3["Nerve-muscle, swallowing or breathing conditions"]
S --> S1["Product name"]
S --> S2["Areas treated"]
S --> S3["Approximate units and date"]
S --> S4["New weakness, swallowing, speech or breathing symptoms"]
S1 --> D["Clinicians decide monitoring site, drug plan and timing"]
S2 --> D
S3 --> D
S4 --> DA practical step makes all of this easier. Ask your injector for a copy of the treatment note showing the product, units, areas and date (and lot number, if recorded), and bring it to your pre-operative appointment. If you cannot get the units, the product name, areas and date are still useful. Our guide to Botox consent forms covers what should be documented and what to expect before you sign.
Evidence Quality and Who This Matters More For
Practice blogs often state their waiting rules with more certainty than the evidence allows. Here is what each type of claim in this article actually rests on.
| Claim | Evidence type | What it shows | Main limitation |
|---|---|---|---|
| Interaction caution with aminoglycosides, curare-like agents and muscle relaxants | FDA labeling (BOTOX Cosmetic, revised 10/2024; BOTOX) | The toxin effect “may be potentiated”; patients should be observed closely | No formal drug interaction studies; no size of effect at cosmetic doses |
| Distant spread of toxin effect | Boxed warning based on postmarketing reports | Symptoms reported hours to weeks after injection; swallowing and breathing problems can be life threatening | Risk described as probably greatest in children treated for spasticity; reported at therapeutic and lower doses; no definitive serious reports at labeled cosmetic doses |
| Facial-nerve twitch monitor misread | Case reports (Eplasty 2019 and earlier reports from 2006 to 2016) | 0 of 4 facial twitches while blockade elsewhere was incomplete | A handful of cases; ICU or unusual settings; toxin presumed rather than confirmed; doses unknown |
| Increased sensitivity to a paralytic drug | One rat study (Anesthesia & Analgesia, 2012) | Atracurium ED50 about one-third of control at the injected muscle on day 16; also lower on the uninjected side | Rats, limb muscle, single dose; cannot be converted to human risk |
| Surgical complications after prior injectables | One retrospective chart review (Dermatologic Surgery, 2026) | 16% vs 8% complications, not statistically significant | Fillers only in the abstract; small single-practice series; no toxin or anesthesia data |
| Specific waiting periods | Practice blogs and physician Q&A answers | Advice ranges from any time to three to four months | Convention and opinion; no comparative trials |
Cosmetic and therapeutic doses are on different scales
Units matter, and so does the product. The BOTOX labels list very different totals for cosmetic and therapeutic uses, and the BOTOX Cosmetic label states that its Units cannot be compared to or converted into Units of any other botulinum toxin product.
| Use | Label | Labeled total dose per treatment |
|---|---|---|
| Glabellar (frown) lines | BOTOX Cosmetic | 20 Units |
| Lateral canthal lines (crow’s feet) | BOTOX Cosmetic | 24 Units |
| Forehead lines with glabellar lines | BOTOX Cosmetic | 40 Units |
| Forehead, glabellar and lateral canthal lines together | BOTOX Cosmetic | 64 Units |
| Platysma (neck) bands | BOTOX Cosmetic | 26 to 36 Units, depending on the number of bands |
| Chronic migraine | BOTOX | 155 Units across 31 head and neck sites |
| Adult upper limb spasticity | BOTOX | Up to 400 Units |
Dose is not a clean safety line. The boxed warning says spread of effect has been reported at doses comparable to those used for cervical dystonia and spasticity “and at lower doses,” with the risk probably greatest in children treated for spasticity. Separately, the label reports no definitive serious distant-spread cases at the labeled cosmetic doses. No study we found shows that a larger toxin dose raises anesthesia risk by a known amount. Larger therapeutic doses are still a reason for the treating specialist and the anesthesia team to talk directly rather than relying on a line on an intake form.
When to expect more scrutiny
Therapeutic or high-dose toxin. If you receive toxin for migraine, spasticity, cervical dystonia or sweating, the totals are usually higher than cosmetic doses, sometimes many times higher. Bring the treating clinician’s details so the anesthesia team can coordinate with them.
Pre-existing nerve-muscle disorders. Label section 5.6 says patients with neuromuscular disorders may be at increased risk of clinically significant effects, including severe swallowing difficulty and respiratory compromise, and names peripheral motor neuropathic diseases, ALS, myasthenia gravis and Lambert-Eaton syndrome. Both clinicians need to know.
Existing swallowing or breathing problems. Label section 5.7 says patients with pre-existing swallowing or breathing difficulties may be more susceptible, and that toxins can weaken neck muscles that act as accessory muscles of breathing.
Head, neck or airway procedures near treated areas. When the operation or airway management involves the same region as recent toxin, for example neck-band treatment before neck surgery or a lip treatment before lip surgery, the surgeon and anesthesia team need the specifics. We found no study of this scenario, so treat it as a reason for an explicit conversation, not as a known complication rate.
New symptoms after an injection. Drooping eyelids, double vision, voice change, or trouble swallowing or breathing after a recent injection call for same-day medical contact, and the surgical team should hear about them before any elective operation goes ahead.
A note on skin of color: none of the sources reviewed reported outcomes by skin type, ethnicity or Fitzpatrick type, and nothing in this evidence suggests the disclosure advice should differ by skin tone. It applies to everyone.
This article does not clear anyone for surgery or set a personal interval. If you are unsure whether to keep, move or cancel an injection appointment, ask the surgeon’s office first; they know the operation, the anesthetic plan and the drugs involved. The short version is simple: keep the toxin details on your pre-operative paperwork, tell your injector about the operation, and let the clinicians giving the anesthetic decide what, if anything, changes.
Sources
U.S. Food and Drug Administration / DailyMed. BOTOX Cosmetic (onabotulinumtoxinA) for injection: Prescribing Information and Medication Guide, revised October 2024. Available from: DailyMed: BOTOX Cosmetic labeling
AbbVie. BOTOX (onabotulinumtoxinA) for injection: full Prescribing Information for therapeutic indications. Available from: AbbVie: BOTOX Prescribing Information (PDF)
Le NK, Liauw D, Siddiqui SZ, Donohue KM. Assessment of Neuromuscular Function in Patients With Prior Cosmetic Procedures: A Case Report. Eplasty. 2019;19:e20. PMID 31885763. Available from: PubMed Central: PMC6916190
Frick CG, Fink H, Blobner M, Martyn J. A Single Injection of Botulinum Toxin Decreases the Margin of Safety of Neurotransmission at Local and Distant Sites. Anesthesia & Analgesia. 2012;114(1):102–109. PMID 22003222. Available from: PubMed Central: PMC3243776
Salsberg J, Motakis D. Does Prior Treatment With Facial Injectables Increase the Risk of Rhytidectomy Complications? Dermatologic Surgery. 2026;52(6):568–570. PMID 41411468. Available from: PubMed: 41411468
American Society of Plastic Surgeons. Botulinum Toxin: patient procedure page. Available from: plasticsurgery.org: Botulinum Toxin
RealSelf. Can I Have Botox Treatment a Week After Non Facial Surgery and a General Anaesthetic? Physician Q&A thread, answers 2011–2015; cited only to document the range of advice patients see. Available from: RealSelf Q&A thread
Sarasota Surgical Arts. Can You Get Botox Before Breast Augmentation Surgery? Practice blog; cited only to document practice convention. Available from: Sarasota Surgical Arts blog
Rafizadeh F. Do You Need to Stop Botox and Filler Before Facial Surgery? Better Plastic Surgery practice blog, August 24, 2026; cited for one surgeon’s stated planning rule. Available from: Better Plastic Surgery blog
